-

PharmaEssentia to Present at the Annual J.P. Morgan Healthcare Conference on January 16, 2025

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global commercial biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference Thursday, January 16, 2025 at 1:45 pm. PST.

A live webcast of management's remarks will be available through the News section of PharmaEssentia’s website at https://us.pharmaessentia.com/news/. Replays of the webcast will be archived on the Company's website for at least 30 days.

About PharmaEssentia
PharmaEssentia (TWSE: 6446), headquartered in Taipei, Taiwan, is a commercial-stage, global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversified pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.

For more information about PharmaEssentia USA, visit our website, LinkedIn or X.

© 2024 PharmaEssentia Corporation. All rights reserved.

Contacts

Investor and Media
Muriel Huang, muriel_huang@pharmaessentia.com

Industry:

PharmaEssentia Corporation

TSE:6446
Release Versions
English

Contacts

Investor and Media
Muriel Huang, muriel_huang@pharmaessentia.com

More News From PharmaEssentia Corporation

PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the latest National Comprehensive Cancer Network (NCCN) Guidelines (Version 1.2025, January 21, 2025) now highlight the substitution of ropeginterferon alfa-2b-njft (BESREMi®) for treating...

CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia

BURLINGTON, Mass.--(BUSINESS WIRE)--Please replace the release dated January 6, 2025, with the following corrected version due to multiple revisions. The updated release reads: PHARMAESSENTIA ANNOUNCES POSITIVE TOPLINE PHASE 3 DATA FROM SURPASS-ET STUDY EVALUATING ROPEGINTERFERON ALFA-2B-NJFT (P1101) FOR ESSENTIAL THROMBOCYTHEMIA SURPASS-ET trial achieved its primary endpoint, demonstrating a durable response in 42.9% of participants in the P1101 group versus 6.0% in the comparator group (p=0.0...

PharmaEssentia Reaffirms its Commitment to Robust and Reliable Access to Interferon Therapies Amid Global Supply Challenges

BURLINGTON, Mass.--(BUSINESS WIRE)--In light of the reported global shortage of Pegasys® (peginterferon alfa-2a), PharmaEssentia (TWSE: 6446), a global biopharmaceutical company, reaffirms its enduring commitment to creating robust and reliable access to critical interferon therapies. Amidst growing global concerns about drug shortages of other therapies, PharmaEssentia’s established cGMP manufacturing network and patient-focused approach enable it to help meet the needs of healthcare providers...
Back to Newsroom